Category Archives: Autoimmun Rev

Emerging role of high mobility group box 1 in ANCA-associated vasculitis.

Emerging role of high mobility group box 1 in ANCA-associated vasculitis.

Autoimmun Rev. 2015 Jul 22;

Authors: Wang C, de Souza AW, Westra J, Bijl M, Chen M, Zhao MH, Kallenberg CG

Abstract
High mobility group box 1 (HMGB1) has been suggested to be involved in the pathogenesis of many autoimmune diseases. In addition to its nuclear functions, extracellular HMGB1 released from activated, injured or dying cells becomes a proinflammatory mediator via binding to various receptors on the surface of responding cells. HMGB1 interacts with various systems involved in inflammation, such as the complement system and the coagulation system. Thus, HMGB1 could amplify inflammation and enhance immune responses in pathophysiology of certain diseases. In the past years, HMGB1 has been studied in several vasculitides including antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, Kawasaki disease, Henoch-Schönlein purpura, Takayasu arteritis and giant cell arteritis. Several studies showed that circulating HMGB1 levels are higher in patients with active disease compared with healthy controls, and levels are associated with disease severity. Further studies on pathogenetic mechanisms revealed pathogenic roles of HMGB1 in some vasculitides. Here we review clinical and experimental studies dealing with the role of HMGB1 in vascular inflammation, and its relation to the manifestations and prognosis of specific vasculitides, in particular ANCA-associated vasculitis.

PMID: 26209906 [PubMed – as supplied by publisher]

Continue reading

Posted in Autoimmun Rev | Leave a comment

Macrophage folate receptor-β (FR-β) expression in auto-immune inflammatory rheumatic diseases: a forthcoming marker for cardiovascular risk?

Related Articles

Macrophage folate receptor-β (FR-β) expression in auto-immune inflammatory rheumatic diseases: a forthcoming marker for cardiovascular risk?

Autoimmun Rev. 2012…

Continue reading

Posted in Autoimmun Rev | Tagged | Leave a comment

HMGB1 in vascular diseases: Its role in vascular inflammation and atherosclerosis.

Related Articles

HMGB1 in vascular diseases: Its role in vascular inflammation and atherosclerosis.

Autoimmun Rev. 2012 Oct;11(12):909-17

Authors: de Souza AW, Westra J,…

Continue reading

Posted in Autoimmun Rev | Tagged | Leave a comment

Vaccination of patients with auto-immune inflammatory rheumatic diseases requires careful benefit-risk assessment.

Related Articles

Vaccination of patients with auto-immune inflammatory rheumatic diseases requires careful benefit-risk assessment.

Autoimmun Rev. 2012 Jun;11(8):572-6

Continue reading

Posted in Autoimmun Rev | Tagged , | Leave a comment

Immune regulatory mechanisms in ANCA-associated vasculitides.

Immune regulatory mechanisms in ANCA-associated vasculitides.

Autoimmun Rev. 2011 Dec;11(2):77-83

Authors: Lepse N, Abdulahad WH, Kallenberg CG, Heeringa P

Abstract

Continue reading

Posted in Autoimmun Rev | Tagged , | Leave a comment

Refractory vasculitis.

Refractory vasculitis.

Autoimmun Rev. 2011 Sep;10(11):702-6

Authors: Rutgers A, Kallenberg CG

Abstract

Refractory vasculitis occurs in 4-5% of patients with…

Continue reading

Posted in Autoimmun Rev | Tagged , | Leave a comment

Dysregulated neutrophil–endothelial interaction in antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides: implications for pathogenesis and disease intervention.

Dysregulated neutrophil–endothelial interaction in antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides: implications for pathogenesis and disease intervention.

Autoimmun…

Continue reading

Posted in Autoimmun Rev | Tagged , | Comments Off on Dysregulated neutrophil–endothelial interaction in antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides: implications for pathogenesis and disease intervention.